Hyberbaric oxygen as sole treatment for severe radiation - induced haemorrhagic cystitis
AUTOR(ES)
Dellis, Athanasios, Papatsoris, Athanasios, Kalentzos, Vasileios, Deliveliotis, Charalambos, Skolarikos, Andreas
FONTE
Int. braz j urol.
DATA DE PUBLICAÇÃO
2017-06
RESUMO
ABSTRACT Purpose To examine the safety and efficacy of hyperbaric oxygen as the primary and sole treatment for severe radiation-induced haemorrhagic cystitis. Materials and methods Hyperbaric oxygen was prospectively applied as primary treatment in 38 patients with severe radiation cystitis. Our primary endpoint was the incidence of complete and partial response to treatment, while the secondary endpoints included the duration of response, the correlation of treatment success-rate to the interval between the onset of haematuria and initiation of therapy, blood transfusion need and total radiation dose, the number of sessions to success, the avoidance of surgery and the overall survival. Results All patients completed therapy without complications with a mean follow-up of 29.33 months. Median number of sessions needed was 33. Complete and partial response rate was 86.8% and 13.2%, respectively. All 33 patients with complete response received therapy within 6 months of the haematuria onset. One patient needed cystectomy, while 33 patients were alive at the end of follow-up. Conclusions Our study suggests the early primary use of hyperbaric oxygen for radiation-induced severe cystitis as an effective and safe treatment option.
Documentos Relacionados
- Is there a role for hyberbaric oxygen as primary treatment for grade IV radiation-induced haemorrhagic cystitis? a prospective pilot-feasibility study and review of literature
- A Novel Approach for the Treatment of Radiation-Induced Hemorrhagic Cystitis with the GreenLight™ XPS Laser
- Interstitial cystitis - intravesical treatment
- Cystoprostatectomy with ileal neobladder for treatment of severe cystitis glandularis in an AIDS patient
- Nitroaromatic radiation sensitizers substitute for oxygen in neocarzinostatin-induced DNA damage.